These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24487722)

  • 1. D-K6L 9 peptide combination with IL-12 inhibits the recurrence of tumors in mice.
    Cichoń T; Smolarczyk R; Matuszczak S; Barczyk M; Jarosz M; Szala S
    Arch Immunol Ther Exp (Warsz); 2014 Aug; 62(4):341-51. PubMed ID: 24487722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
    Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
    Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice.
    Kubo H; Matsumoto K; Funahashi M; Takagi H; Kitajima Y; Taniguchi S; Saida T
    Melanoma Res; 2000 Jun; 10(3):223-9. PubMed ID: 10890375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice.
    Jarosz-Biej M; Smolarczyk R; Cichoń T; Kułach N; Czapla J; Matuszczak S; Szala S
    Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):451-64. PubMed ID: 25801067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
    Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
    Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.
    Quetglas JI; Dubrot J; Bezunartea J; Sanmamed MF; Hervas-Stubbs S; Smerdou C; Melero I
    Mol Ther; 2012 Sep; 20(9):1664-75. PubMed ID: 22735380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma.
    Lucas ML; Heller L; Coppola D; Heller R
    Mol Ther; 2002 Jun; 5(6):668-75. PubMed ID: 12027550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasostatin increases oxygenation of B16-F10 melanoma tumors and raises therapeutic efficacy of cyclophosphamide.
    Cichoń T; Jarosz M; Smolarczyk R; Ogórek B; Matuszczak S; Wagner M; Mitrus I; Sochanik A; Jazowiecka-Rakus J; Szala S
    Acta Biochim Pol; 2012; 59(3):377-81. PubMed ID: 22946026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma.
    Lucas ML; Heller R
    DNA Cell Biol; 2003 Dec; 22(12):755-63. PubMed ID: 14683586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of tumor growth by interleukin 10 gene transfer in B16(F10) melanoma cells.
    Walos S; Szary J; Szala S
    Acta Biochim Pol; 1999; 46(4):967-70. PubMed ID: 10824866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice.
    Mitrus I; Delić K; Wróbel N; Missol-Kolka E; Szala S
    Acta Biochim Pol; 2006; 53(2):357-60. PubMed ID: 16733559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of in vivo tumor growth by the transfection of the interleukin-5 gene into colon tumor cells.
    Masuda Y; Mita S; Sakamoto K; Ishiko T; Ogawa M
    Cancer Immunol Immunother; 1995 Dec; 41(6):325-30. PubMed ID: 8635189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting.
    Villaverde MS; Combe K; Duchene AG; Wei MX; Glikin GC; Finocchiaro LM
    Int Immunopharmacol; 2014 Sep; 22(1):167-75. PubMed ID: 24973616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma.
    Yang LP; Cheng P; Peng XC; Shi HS; He WH; Cui FY; Luo ST; Wei YQ; Yang L
    J Exp Clin Cancer Res; 2009 Jun; 28(1):75. PubMed ID: 19500366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cocktail of polyclonal affinity enriched antibodies against melanoma mutations increases binding and inhibits tumor growth.
    Shukla GS; Sun YJ; Pero SC; Krag DN
    J Immunol Methods; 2020 Mar; 478():112720. PubMed ID: 31812660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ilexgenin A induces B16-F10 melanoma cell G1/S arrest in vitro and reduces tumor growth in vivo.
    Yang H; Liu C; Zhang YQ; Ge LT; Chen J; Jia XQ; Gu RX; Sun Y; Sun WD
    Int Immunopharmacol; 2015 Feb; 24(2):423-431. PubMed ID: 25596038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.